

August 1, 2018

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Mothers Code: 4593)

Athersys Announces Enrollment of First Patient in MASTERS-2 Phase 3 Study of MultiStem[®] Treatment for Ischemic Stroke

HEALIOS K.K. (“Healios”) is developing a new treatment for acute ischemic stroke in Japan using the stem cell product MultiStem[®], for which the patent and licensing rights are held by Athersys, Inc (“Athersys”).

We are delighted to announce that Athersys announced that the first patient has been enrolled its Phase 3 study entitled, *MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2* (“MASTERS-2”) to evaluate MultiStem cell therapy treatment of patients who have suffered an ischemic stroke.

An announcement from Athersys can be found at the following link:

<http://www.athersys.com/news-releases/news-release-details/athersys-announces-enrollment-first-patient-masters-2-phase-3>

About HLCM051

Healios is developing new cell therapy to treat patients with acute ischemic stroke in Japan using HLCM051, a somatic stem cell regenerative medicine product.

Ischemic stroke is a condition in which a blockade in blood vessels in the brain precludes the delivery of oxygen and nutrients beyond the blockade, causing necrosis of nerve cells over time. Currently, ischemic stroke is treated with t-PA (a thrombolytic agent) that dissolves clots lodged in a blood vessel in the brain, mechanical reperfusion therapy, or other treatment options; however, there is a need for a new drug that can be used during a longer period of time after the onset of ischemic stroke.

Healios has introduced this pipeline by signing an exclusive licensing agreement with Athersys, Inc. in January 2016. Currently Healios is conducting a randomized, double-blind, placebo-controlled Phase 2/3 trial (TREASURE study) designed to confirm the efficacy and safety of HLCM051 in treating patients with ischemic stroke. Patients will receive a single intravenous infusion of HLCM051 or placebo within 18-36 hours of stroke onset and a total of 220 patients will be enrolled.

Contact:

Department of Public Relations, HEALIOS K.K.

Mail: pr@healios.jp